Stockpolly
Search
Delisting risk
FEMY · NASDAQ · Medical - Instruments & Supplies

Femasys (FEMY)

Catheter-based fertility diagnostics, treatment, and permanent-contraception development.

$3.11
At close−0.15 (−4.60%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000011001100
Cost of revenue000000001000
Gross profit000000000100
454555644645
Research & development222222311212
222333333333
Selling & marketing000121111111
General & administrative222222221222
Other expenses000000000100
Operating income−4−4−3−4−5−5−5−4−4−5−4−5
0000000−1−1151
Interest income000000000000
Interest expense000000001000
Other non-operating income000000000−1−5−1
Income before tax−4−4−4−5−5−5−6−5−4−41−4
Income tax expense000000000010
Net income from continuing operations−4−4−4−5−5−5−6−5−4−40−4
Net income−4−4−4−5−5−5−6−5−4−40−4
EPS, basic−$0.26−$4.00−$3.40−$4.20−$4.80−$4.40−$4.60−$3.20−$2.00−$1.33$0.10−$1.33
EPS, diluted−$0.26−$4.00−$3.40−$4.20−$4.80−$4.40−$4.60−$3.20−$2.00−$1.33$0.08−$1.33
Weighted average shares, basic15—————————33
Weighted average shares, diluted15—————————43
EBITDA−4−4−3−4−5−4−5−4−3−31−4
Depreciation & amortization000000000000
EBIT−4−4−3−4−5−5−5−4−4−41−4